| Literature DB >> 32160882 |
Hebing Guo1, Jingyuan Liu1, Lin Pu1, Jingjing Hao1, Ningning Yin1, Yufeng Liu1, Haofeng Xiong1, Ang Li2.
Abstract
BACKGROUND: Acute kidney injury (AKI) is a common complication among human immunodeficiency virus (HIV)-infected patients resulting in increased morbidity and mortality. Continuous renal replacement therapy (CRRT) is a useful method and instrument in critically ill patients with fluid overload and metabolic disarray, especially in those who are unable to tolerate the intermittent hemodialysis. However, the epidemiology, influence factors of CRRT and mortality in patients with HIV/AIDS are still unclear in China. This study aims to study the HIV-infected patients admitted in Intensive Care Unit (ICU) and explore the influence factors correlated with CRRT and their prognosis.Entities:
Keywords: CRRT; HIV/AIDS; Mortality; Risk factors
Mesh:
Year: 2020 PMID: 32160882 PMCID: PMC7066780 DOI: 10.1186/s12882-020-01754-4
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Study flow chart detailing the inclusion and exclusion of patients
Demographic and Clinical Characteristics of 122 AKI Patients Admitted to the Intensive Care Unit
| Patients with AKI | Patients with CRRT | Patients without CRRT | ||
|---|---|---|---|---|
| Male(%) | 112 (91.8) | 31 (96.9) | 81 (90) | 0.452 |
| Age(years) | 41 (34–50) | 42 (37–55.5) | 41 (31–50) | 0.137 |
| Lymphocyte count(× 109) | 0.5 (0.3–0.92) | 0.54 (0.34–1.10) | 0.5 (0.30–0.80) | 0.205 |
| Hemoglobin(g/L) | 98.9 ± 27.4 | 90.7 ± 23.8 | 101.8 ± 28.1 | |
| Albumin (g/L) | 28.0 ± 5.8 | 29.3 ± 4.9 | 27.5 ± 6.1 | 0.154 |
| Total Bilirubin (u mol/L) | 8.65 (5.38–13.43) | 7.75 (5.03–15.33) | 9.15 (5.4–13.43) | 0.682 |
| Serum calcium(mmol/L) | 1.92 (1.77–2.09) | 2.00 (1.67–2.19) | 1.92 (1.82–2.05) | 0.375 |
| CD4 counts at ICU admission | 23 (8–78) | 37 (13–122) | 15 (7–69) | |
| Patients with HAART | 30 (24.6) | 11 (34.4) | 19 (21.1) | 0.135 |
| The first Creatinine in Hospital (u mol/L) 72.7 (54–129.3) | 220.1 (70.9–499.1) | 64.5 (51.8–92.6) | ||
| The highest Creatinine before in ICU(u mol/L)48.9 (34.7–70.8) | 194.2 (55.4–441.5) | 42.1 (32.8–58.6) | ||
| The highest Creatinine during ICU(u mol/L) 159.6 (85.6–331) | 375.4 (293.3–580.0) | 121.6 (79.4–210.5) | ||
| Sepsis (%) | 104 (85.2) | 25 (78.1) | 79 (87.8) | 0.245 |
| Septic Shock(%) | 74 (60.7) | 19 (59.4) | 55 (61.1) | 0.863 |
| PCP (%) | 71 (58.2) | 12 (37.5) | 59 (65.6) | |
| Respiratory Failure (%) | 81 (66.4) | 15 (46.9) | 65 (72.2) | |
| The use of vasoactive agents (%) | 81 (66.4) | 22 (68.8) | 59 (65.6) | 0.742 |
| Duration of Mechanical ventilation (h) | 131.5 (16–264) | 141.5 (5–225.5) | 124.5 (24–264.0) | 0.788 |
| SOFA score at ICU admission | 8 (4–12) | 12 (6–16) | 7 (4–10) | |
| APACHE-II score at ICU admission | 20 (15–28) | 28 (21–34) | 18 (15–23) | |
| Death during in ICU | 61 (50) | 18 (56.3) | 43 (47.8) | 0.41 |
| Length of ICU stay (days), median (IQR) | 9 (5–16) | 8 (5–16) | 9 (5–17) | 0.616 |
| Length of hospital stay (days), median (IQR) | 17 (9–30) | 15 (7–21) | 20 (10–34) | |
ICU Intensive care unit, HIV Human immunodeficiency virus, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, SOFA, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment, GFR Glomerular Filtration Rate, MPV Mean Platelet Volume
p Value < 0.05 was considered significant and is highlighted in bold
Fig. 2Cause for admission ICU and death number of the 32 CRRT patients
Univariate Analysis for the Identification of Predictors the Death of CRRT in ICU
| Odds ratio | 95% Confidence interval | ||
|---|---|---|---|
| Respiratory Failure | 7.333 | 1.467–36.664 | |
| Septic Shock | 1.005 | 1.001–1.010 | |
| The use of vasoactive agents | 10.667 | 1.743–65.271 | |
| Duration of Mechanical Ventilation | 1.011 | 1.002–1.019 | |
| PCP | 7.50 | 1.288–43.687 | |
| SOFA score at ICU admission | 1.183 | 1.012–1.383 | |
| Duration of CRRT | 1.014 | 1.001–1.028 |
CRRT Continuous renal replacement therapy, ICU Intensive care medicine, SOFA Sequential organ failure assessment, PCP Pneumocystis carinii pneumonia
p Value < 0.05 was considered significant and is highlighted in bold
The comparison between Patients with CRRT and non-CRRT who were in AKI stage 3
| AKI stage 3 ( | CRRT ( | non-CRRT ( | ||
|---|---|---|---|---|
| Male(%) | 57 (90.5) | 31 (96.9) | 26 (83.9) | 0.104 |
| Age(years) | 43 (37–50) | 42 (37–56) | 44 (36–48) | 0.527 |
| Lymphocyte count(×109) | 0.5 (0.24–1.00) | 0.54 (0.34–1.05) | 0.5 (0.2–0.8) | 0.146 |
| Hemoglobin(g/L) | 91 (70.8–108) | 91 (71.8–109.5) | 89 (70.7–104.5) | 0.929 |
| Albumin(g/L) | 27.4 (23.8–31.7) | 30.3 (24.9–32.5) | 26.8 (22.3–30.2) | |
| T-Bil (umol/L) | 8.7 (5.8–15.9) | 7.8 (5.1–14.5) | 11.4 (6.3–16.0) | 0.343 |
| Serum calcium(mmol/L) | 1.92 (1.71–2.09) | 2.0 (1.68–2.18) | 1.88 (1.74–2.03) | 0.221 |
| Lactate (mmol/L) | 2.8 (1.45–6.05) | 3.65 (1.55–7.15) | 2.1 (1.35–5.0) | 0.091 |
| Serum phosphate(mmol/L) | 1.11 (0.81–1.65) | 1.45 (0.81–1.88) | 1.02 (0.81–1.36) | 0.159 |
| LDH (U/L) | 450 (309.6–786.6) | 501 (281.6–1233) | 450 (321.2–663.2) | 0.336 |
| CD4 counts at ICU admission(cells/ml) | 24 (8–86) | 37 (13–116) | 11 (5–36) | |
| HIV viral load (copies/mL) | 1700 (90–249,112) | 1650 (0–174,710) | 37,444 (1142–335,614) | 0.116 |
| HAART(%) | 26 (41) | 10 (31) | 16 (51.6) | 0.052 |
| PCP (%) | 30 (47.6) | 12 (37.5) | 18 (58.1) | 0.102 |
| Septic Shock(%) | 41 (65.1) | 19 (59.4) | 22 (71) | 0.245 |
| Multiple Organs Support Therapy | ||||
| The use of vasoactive agents(%) | 46 (73) | 22 (66.8) | 24 (77.4) | 0.349 |
| Duration of Mechanical ventilation (h) | 120 (7–240) | 142 (5–256) | 119 (14–212.5) | 0.825 |
| Severity of illness | ||||
| SOFA score at ICU admission (scores) | 9 (7–13) | 11 (7–14) | 9 (6–11) | 0.094 |
| APACHE-II score at ICU admission(scores) | 23 (19–33) | 28 (22–35) | 19 (18–30) | |
| Death during in ICU | 34 (54) | 18 (56) | 14 (45.2) | 0.521 |
| Renal recovery | 17 (27.0) | 7 (21.9) | 10 (32.3) | 0.353 |
| Length of ICU stay (days), median (IQR) | 8 (5–14) | 8 (5–15) | 6 (5–14) | 0.679 |
| Length of hospital (days), median (IQR) | 16 (9–29) | 15 (7–21) | 17 (12–38) | |
T-Bil Total bilirubin, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, ICU Intensive care unit, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment
p Value < 0.05 was considered significant and is highlighted in bold
Fig. 3Cumulative survival curves of HIV infected patients who were diagnosed with AKI 3 admitted to the intensive care unit, received CRRT or not received (two groups)
The Cox Analysis for the cumulative survival of AKI 3 patients between the CRRT and non-CRRT groups
| Odds ratio | 95% Confidence interval | ||
|---|---|---|---|
| CRRT | 1.236 | 0.566–2.70 | 0.595 |
| The possibility of using vasoactive agents | 12.621 | 1.637–97.293 | |
| SOFA score at ICU admission | 0.978 | 0.896–1.068 | 0.625 |
| PCP | 0.831 | 0.362–1.909 | 0.663 |
CRRT Continuous renal replacement therapy, ICU Intensive care unit, SOFA Sequential organ failure assessment, PCP Pneumocystis carinii pneumonia
p Value < 0.05 was considered significant and is highlighted in bold